Clinical Trial Detail

NCT ID NCT03292133
Title A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Massachusetts General Hospital
Indications

lung non-small cell carcinoma

Therapies

Gefitinib + Nazartinib

Age Groups: senior adult

No variant requirements are available.